human prostate tissue microarray (cancer) (Bio-Techne corporation)
Bio-Techne corporation is a verified supplier 
Bio-Techne corporation manufactures this product 
94
Structured Review
Bio-Techne corporation
human prostate tissue microarray (cancer)
Human Prostate Tissue Microarray (Cancer), supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 24 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+prostate+tissue+microarray+slides/Human+Prostate+Tissue+MicroArray+(Cancer)/custom%40nbp2-30169%4036084759
Average 94 stars, based on 24 article reviews
Human Prostate Tissue Microarray (Cancer), supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 24 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+prostate+tissue+microarray+slides/Human+Prostate+Tissue+MicroArray+(Cancer)/custom%40nbp2-30169%4036084759
Average 94 stars, based on 24 article reviews
human prostate tissue microarray (cancer) - by Bioz Stars,
2026-11
94/100 stars
Images
Related Articles
Recombinant:Article Title: Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis. Article Snippet: static prostate tumours and indicates the Siglec-sialoglycan axis can be clinically targeted to impede prostate cancer progression. TMA cohort 1. A 40 case human prostate cancer TMA was purchased from Microarray:Article Title: Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis. Article Snippet: static prostate tumours and indicates the Siglec-sialoglycan axis can be clinically targeted to impede prostate cancer progression. TMA cohort 1. A 40 case human prostate cancer TMA was purchased from Immunohistochemistry:Article Title: Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis. Article Snippet: static prostate tumours and indicates the Siglec-sialoglycan axis can be clinically targeted to impede prostate cancer progression. TMA cohort 1. A 40 case human prostate cancer TMA was purchased from Immunofluorescence:Article Title: Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis. Article Snippet: static prostate tumours and indicates the Siglec-sialoglycan axis can be clinically targeted to impede prostate cancer progression. TMA cohort 1. A 40 case human prostate cancer TMA was purchased from Imaging:Article Title: Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis. Article Snippet: static prostate tumours and indicates the Siglec-sialoglycan axis can be clinically targeted to impede prostate cancer progression. TMA cohort 1. A 40 case human prostate cancer TMA was purchased from Staining:Article Title: Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis. Article Snippet: static prostate tumours and indicates the Siglec-sialoglycan axis can be clinically targeted to impede prostate cancer progression. TMA cohort 1. A 40 case human prostate cancer TMA was purchased from |